Georgia's Online Cancer Information Center

Find A Clinical Trial

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Status
Active
Cancer Type
Leukemia
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04260022
Protocol IDs
HQP1351CU101 (primary)
NCI-2020-01100
Study Sponsor
Ascentage Pharma Group Inc.

Summary

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK)
of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with
CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have
experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in
subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have
experienced resistance or intolerance to at least one second or later generation TKI.

Objectives

Approximately 40 patients will be randomized at 3:3:2 ratio into one of three HQP1351
monotherapy dose cohorts (Cohort A, B, and C): 30 mg every other day (QOD), 40 mg QOD, and 50
mg QOD, with 15, 15, and 10 patients in Cohort A, B, and C. The first cycle of 28 days is
considered as the dose-limiting toxicity (DLT) observation period. If the incidence of DLTs
exceeds 20% (2 patients) in 50 mg dose cohort during the first cycle of therapy, this dose
cohort will be stopped. The randomization will be stratified to 4 groups: T315I mutated
CML-CP and CML-AP, T315I un-mutated CML-CP, T315I unmutated CML-AP, and CML-BP and Ph+ ALL to
ensure that the subgroups are represented across all dose cohorts. Blood samples will be
collected from each subject at specified time points to evaluate the PK of HQP1351. RP2D of
HQP1351 will be determined based on the comprehensive analyses of the PK, safety, and
efficacy data of the US patients treated with HQP1351, when compared with that in the Chinese
patients.

Eligible patients will have disease resistance to or intolerance to at least two TKIs, for
patients with T315I mutation, number of pretreated TKIs is not restricted. Patients will be
administered HQP1351 orally QOD during a period of 28 days (1 cycle).

Cohort D (HQP1351 + blinatumomab) will enroll patients with relapsed/refractory Ph+ BCP ALL
or CML-BP using a dose escalation and expansion design. Patients will be administered HQP1351
orally QOD at an assigned dose with blinatumomab at repeated 42-day cycles. The first cycle
of 42 days is considered as the DLT observation period. The initial dose of HQP1351 will be
30 mg QOD.

Eligibility

  1. For HQP1351 monotherapy, patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL, with or without T315I mutation
  2. For Cohort D, patients with Ph+ BCP ALL or CML LBP must be resistant or intolerant to at least one second or later generation TKI, such as dasatinib, nilotinib, bosutinib and ponatinib, despite optimal supportive care
  3. For HQP1351 monotherapy only: Be previously treated with and developed resistance or intolerance to at least two TKIs including ponatinib, imatinib, dasatinib, nilotinib, bosutinib, and asciminib. For patients with a T315I mutation, number of pretreated TKIs is not restricted.
  4. The definition of resistance to first-line TKI treatment refers to European Leukemia Net (ELN) recommendations. The definitions are the same for patients in CP, AP, BP, and Ph+ ALL, and apply also to second-line treatment, when first-line treatment was changed for intolerance. The patients must meet at least one criterion:
  5. Three months after the initiation of therapy: non-complete hematologic response (CHR) and/or Ph+ >95%
  6. Six months after the initiation of therapy: BCR-ABL1>10% and/or Ph+ >35%
  7. Twelve months after the initiation of therapy: BCR-ABL1>1% and/or Ph+ >0%
  8. Then, and at any time after the initiation of therapy: Loss of CHR, or loss of complete cytogenetic response (CCyR), or confirmed loss of major molecular response (MMR) (In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level =1%), mutations, clonal chromosome abnormalities in Ph+ cells (CCA/Ph+)
  9. The definition of resistance to second-line TKI treatment a) For CML CP patients: the patients must meet at least one criterion as follows: i.) Three months after the initiation of therapy: No CHR or Ph+ >95% or new mutations ii.) Six months after the initiation of therapy: BCR-ABL1>10% and/or Ph+ >65% and/or new mutations iii.) Twelve months after the initiation of therapy: BCR-ABL1>1% and/or Ph+ >35% and/or new mutations iv.) Then, and at any time after the initiation of therapy: Loss of CHR or loss of CCyR, new mutations, confirmed loss of MMR (In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level =1%), clonal chromosome abnormalities in Ph+ cells (CCA/Ph+) b) For CML AP patients: the patients must meet at least one criterion as follows: i.) Three months after the initiation of therapy: failure to achieve a major hematologic response (MaHR) ii.) At any time after the initiation of therapy, the loss of a MaHR, confirmed in at least 2 consecutive analyses separated by at least 4 weeks iii.) At any time after the initiation of therapy, the development of new BCR-ABL kinase domain mutations in the absence of a MaHR c) For CML BP and Ph+ ALL patients: the patients must meet at least one criterion as follows: i) One month after the initiation of therapy: failure to achieve a MaHR ii) At any time after the initiation of therapy, the loss of a MaHR, confirmed in at least 2 consecutive analyses separated by at least 1 week iii) At any time after the initiation of therapy, the development of new BCR-ABL kinase domain mutations in the absence of a MaHR
  10. Intolerance to TKIs is defined as:
  11. Non-hematological AEs: patients with grade 3 or 4 toxicity during TKIs treatment, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments in the absence of a CCyR for CP patients or MaHR for AP/BP or Ph+ ALL patients
  12. Hematological AEs: patients with grade 3 or 4 toxicity during TKIs treatment, that is recurrent after unresponsive after optimal management, including dose adjustments in the absence of a CCyR for CP patients or MaHR for AP/BP or Ph+ ALL patients
  13. Patients providing written informed consent before initiation of any study-related activities
  14. Eastern Cooperative Oncology Group (ECOG) performance status =2
  15. Minimum life expectancy of 3 months or more
  16. Patients with adequate organ function as defined below:
  17. Creatinine < 2 × upper limit of normal (ULN); or, creatinine > 2 × ULN, with 24h glomerular filtration rate (GFR) = 30 mL/min (Cockcroft-Gault)
  18. Serum albumin = 3.0 g/dL
  19. Total bilirubin < 1.5 × ULN
  20. Aspartate aminotransferase (AST [Serum glutamic oxaloacetic transaminase (SGOT)]) and alanine aminotransferase (ALT [serum glutamate-pyruvate transaminase (SGPT)]) < 3 × ULN for institution (<5×ULN if liver involvement with leukemia)
  21. Serum amylase and lipase = 1.5 × ULN
  22. Prothrombin time (PT) = 1.5 × ULN
  23. Heart function: Left ventricular ejection fraction (LVEF) > 50%
  24. Normal QT interval corrected Fridericia (QTcF) interval on screening electrocardiogram (ECG) evaluation: male =450ms, female =470ms
  25. For females of childbearing potential, a negative pregnancy test must be established before enrollment. And the eligible female and male patients with childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study
  26. Ability to comply with study procedures, in the Investigator's opinion

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.